Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.
Source: BioPharma Dive
You may also like
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.